| Literature DB >> 31662393 |
Nicole Evangelidis1,2, Jonathan Craig2,3, Adrian Bauman4, Karine Manera4,2, Valeria Saglimbene4,2, Allison Tong4,2.
Abstract
OBJECTIVES: Modifying lifestyle can prevent the progression of chronic kidney disease (CKD) but the specific elements which lead to favourable behaviour change are not well understood. We aimed to identify and evaluate behaviour change techniques and functions in lifestyle interventions for preventing the progression of CKD.Entities:
Keywords: Behaviour Change Technique Taxonomy v1; behaviour change techniques; chronic kidney disease (CKD); diet; exercise; health behaviour change wheel; lifestyle; systematic review
Year: 2019 PMID: 31662393 PMCID: PMC6830616 DOI: 10.1136/bmjopen-2019-031625
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1PRISMA flowchart of included/excluded studies. *A behavioural intervention explicitly describes a behaviour change technique which can be coded using the Behavior Change Technique Taxonomy v1. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Characteristics of included studies
| Study | N | CKD Stage | Age (years) | Country | Intervention | Comparator | Primary Outcomes | Study duration (months) |
|
| ||||||||
| Campbell | 56 | CKD4–5 | >18 | Australia | Individualised nutritional counselling and regular follow-up | Usual care | Body composition | 3 |
| Clark | 590 | CKD3 | 18–80 | Canada | Coaching to increase water intake (drinking containers and water vouchers also provided) | Coaching to maintain usual fluid intake | Change in eGFR | 12 |
| De Brito-Ashurst | 56 | eGFR <60 mL and BP >130/80 or taking BP medication; Bangladeshi origin | 18–74 | United Kingdom | Community cooking education sessions facilitated by Bengali workers | Usual care | Reduction in systolic/diastolic BP | 6 |
| Dussol | 63 | Type I/II diabetic nephropathy, eGFR60-100 mL | 40–72 | France | Low-protein diet with telephone calls every 6 weeks to help change dietary habits | Usual-protein diet | Decline GFR and 24-hour albumin excretion rate | 24 |
| MDRD Study (1995)* | 840 | eGFR 13–55 mL | 18–70 | United States | Low protein diet with dietician support | Moderate, low and very low protein diets compared | Decline eGFR, dietary satisfaction | 45 |
| Mekki | 40 | eGFR 60–90 mL | 47–75 | Algeria | Nutritional advice based on Mediterranean diet | Usual care | Dyslipidaemia | 3 |
| Meuleman | 138 | eGFR ≥20 mL | ≥18 | The Netherlands | Sodium restricted diet with self-management, education, motivational interviewing and self-monitoring | Usual care | Sodium excretion & BP | 3 |
| Paes-Barreto | 89 | CKD3–5 | ≥18 | Brazil | Intense counselling/education on low protein diet | Standard counselling | Change in protein intake | 4 |
| Pisani | 57 | CKD3b–5 | >18 | Italy | Low protein, phosphate and sodium diet, ‘6-tips diet’ checklist | Non-individualised, moderately low protein diet | Protein intake, metabolic parameters and adherence | 6 |
| Rosman | 247 | CrCl 10–60 mL/min | 15–73 | The Netherlands | Dietary protein restriction and dietician visits every 3 months | Usual care | Adherence | 24 |
| Saran | 58 | CKD3–4 | >18 | United States | Dietary sodium restriction (<2 g sodium per day) | Usual diet | Change in hydration status | 1 |
|
| ||||||||
| Aoike | 29 | CKD3–4 | 18–70 | Brazil | Home-based moderate-intensity aerobic exercise programme | Usual care | Cardiopulmonary/functional, BP, CrCl, eGFR | 3 |
| Barcellos | 150 | CKD2–4 | >18 | Brazil | Aerobic and resistance training | Usual care | Change in eGFR | 4 |
| Greenwood | 20 | CKD3–4 | 18–80 | United Kingdom | Resistance and aerobic training (3 days per week) | Usual care | Change in eGFR | 12 |
| Kao | 94 | eGFR ≥15 mL | ≥39 | Taiwan | Group education lecture; individual exercise programme Trans-Theoretical Model | Not specified | Exercise behaviour, depression, fatigue | 3 |
| Leehey | 32 | CKD2–4 | 49–81 | United States | Aerobic & resistance training, home exercise (plus dietary management) | Dietary management | Urine protein to creatinine ratio | 12 |
| Rossi | 107 | CKD3–4 | ≥18 | United States | Guided exercise twice a week plus usual care | Usual care | Physical function, quality of life | 3 |
| Tang | 90 | CKD1–3 | 18–70 | China | Individualised exercise programme (education and home-based aerobic exercise) | Usual care | Physical function, self-efficacy, anxiety, depression, quality of life | 3 |
| Van Craenenbroeck | 40 | CKD3–4 | ≥18 | Belgium | Home-based aerobic training programme (four daily cycling sessions, 10 min each) | Usual care | Peripheral endothelial function | 3 |
|
| ||||||||
| Flesher | 40 | CKD3–4 | 18–80 | Canada | Individual dietary counselling, group nutrition and cooking classes, exercise programme | Usual care | Composite eGFR, TC, urinary sodium, urinary protein and BP | 12 |
| Howden | 83 | CKD3–4 | 18–75 | Australia | Multi-disciplinary care, lifestyle and aerobic/resistance training | Usual care | Change in CRF | 12 |
| Ishani | 601 | eGFR <60 | >18 | USA | Care by a multi-disciplinary team using a telehealth device | Usual care | Composite death, hospitalisation, emergency visits and admission to a nursing facility | 20 |
| Jiamjariyapon | 442 | CKD3–4 | 18–70 | Thailand | Integrated care by multi-disciplinary team and community care workers. Group counselling, home visits | Usual care | Change in eGFR | 24 |
| Joboshi and Oka | 65 | Overt proteinuria and clinically diagnosed CKD | 38–86 | Japan | Self-management programme | Standard education | Self-efficacy and self-management behaviour | 3 |
| Patil | 76 | Diabetic nephropathy | 30–70 | India | Low-calorie diet, physical activity and behaviour | ACE inhibitor therapy | 24-hour urine protein BMI | 6 |
| Teng | 160 | eGFR ≥30 mL/min/1.73 m2 | ≥20 | Taiwan | Lifestyle modification programme based on Trans-Theoretical Model | Standard education | Health behaviours, knowledge, physical function | 12 |
*MDRD study described in two main articles: Gillis et al 33 and Coyne et al 48.
BMI, Body Mass Index; BP, blood pressure;CKD, chronic kidney disease; CrCl, creatinine clearance; CRF, cardiorespiratory fitness; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease study; TC, total cholesterol.
Figure 2Risk of bias for individual studies (n=26). MDRD, Modification of Diet in Renal Disease study.
Cross matrix of behaviour change techniques and lifestyle behaviour change trials
| Meuleman | MDRD Study (1995)* | De Brito-Ashurst | Paes-Barreto | Campbell | Rosman | Dussol | Pisani | Saran | Clark | Mekki e | Tang | Kao | Greenwood | Rossi | Aoike | Barcellos | Van Craenenbroeck | Leehey | Howden | Ishani | Joboshi and Oka | Teng | Flesher | Jiamjariyapon | Patil | |
| Diet | Physical Activity | Lifestyle | ||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 1.1. Goal setting (behaviour) | ||||||||||||||||||||||||||
| 1.2. Problem solving | ||||||||||||||||||||||||||
| 1.3. Goal setting (outcome) | ||||||||||||||||||||||||||
| 1.4. Action planning | ||||||||||||||||||||||||||
| 1.5. Review behaviour goal(s) | ||||||||||||||||||||||||||
| 1.7. Review outcome goal(s) | ||||||||||||||||||||||||||
| 1.8. Behavioural contract | ||||||||||||||||||||||||||
| 1.9. Commitment | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 2.1. Monitoring of behaviour by others without feedback | ||||||||||||||||||||||||||
| 2.2. Feedback on behaviour | ||||||||||||||||||||||||||
| 2.3. Self-monitoring of behaviour | ||||||||||||||||||||||||||
| 2.4. Self-monitoring of outcome(s) of behaviour | ||||||||||||||||||||||||||
| 2.6. Biofeedback | ||||||||||||||||||||||||||
| 2.7. Feedback on outcome(s) of behaviour | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 3.1. Social support (unspecified) | ||||||||||||||||||||||||||
| 3.2. Social support (practical) | ||||||||||||||||||||||||||
| 3.3. Social support (emotional) | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 4.1. Instruction on behaviour | ||||||||||||||||||||||||||
| 4.4. Behavioural experiments | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 5.1. Information about health consequences | ||||||||||||||||||||||||||
| 5.2. Salience of consequences | ||||||||||||||||||||||||||
| 5.4. Monitoring of emotional consequences | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 6.1. Demonstration of the behaviour | ||||||||||||||||||||||||||
| 6.2. Social comparison | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 7.1. Prompts/cues | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 8.1. Behavioural practice/rehearsal | ||||||||||||||||||||||||||
| 8.2. Behaviour substitution | ||||||||||||||||||||||||||
| 8.4. Habit reversal | ||||||||||||||||||||||||||
| 8.6. Generalisation of target behaviour | ||||||||||||||||||||||||||
| 8.7. Graded tasks | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 9.2. Pros and cons | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 10.3. Non-specific reward | ||||||||||||||||||||||||||
| 10.4. Social reward | ||||||||||||||||||||||||||
| 10.10. Reward (outcome) | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 11.2. Reduce negative emotions | ||||||||||||||||||||||||||
| 11.3. Conserving mental resources | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 12.5. Adding objects to the environment | ||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||
| 15.1. Verbal persuasion capability | ||||||||||||||||||||||||||
| 15.3. Focus on past success | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*MDRD study described in two main articles: Gillis et al 33 and Coyne et al 48.
BCT, Behaviour Change Technique.
Cross matrix of intervention functions and lifestyle behaviour change trials
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
| Campbell |
| |||||||
| Clark | ||||||||
| De Brito-Ashurst | ||||||||
| Dussol | ||||||||
| MDRD Study (1995)* | ||||||||
| Mekki | ||||||||
| Meuleman | ||||||||
| Paes-Barreto | ||||||||
| Pisani | ||||||||
| Rosman | ||||||||
| Saran | ||||||||
| Aoike |
| |||||||
| Barcellos | ||||||||
| Greenwood | ||||||||
| Kao | ||||||||
| Leehey | ||||||||
| Rossi | ||||||||
| Tang | ||||||||
| Van Craenenbroeck | ||||||||
| Flesher |
| |||||||
| Howden | ||||||||
| Ishani | ||||||||
| Jiamjariyapon | ||||||||
| Joboshi | ||||||||
| Patil | ||||||||
| Teng | ||||||||
|
|
|
|
|
|
|
|
| |
*MDRD study described in two main articles: Gillis et al 33 and Coyne et al.48
Effects of the behaviour change interventions on the primary outcome(s)
| Study | Primary outcome/s | Measures | Intervention (n) | Control (n) | Intervention* | Control* | Mean difference (95% CI) | P value |
|
| ||||||||
| Campbell | Body composition | Body cell mass, % | 29 | 27 | 2.0 (1.9 to 5.9)† | 1.5 (5.5 to 2.5)† | 3.5 (2.1 to 9.1) | 0.2 |
| Body cell mass, kg | 0.5 (1.8 to 0.8)† | 0.5 (0.7 to 1.8)† | 1.1 (0.7 to 2.9) | 0.2 | ||||
| Clark | Change in eGFR | Change eGFR, mL/min/1.73 m2 | 311 | 308 | −2.2 (−3.3 to −1.1)† | −1.9 (−2.9 to −0.9)† | −0.3 (−1.8 to 1.2) | 0.74 |
| De Brito-Ashurst | Change in BP | Reduction systolic/diastolic BP | 25 | 23 | – | – | −8 mm Hg (−11 to −5)/2 (−4 to −2) | <0.001 |
| Dussol | Decrease in eGFR | Decrease eGFR, mL/min/1.73 m2 | 25 | 22 | −7±11 | −5±15 | – | – |
| 24-hour albumin excretion rate | Microalbuminuria, mg/d | +114±364 | +156±486 | – | – | |||
| MDRD‡ Study 1 (1995) | Dietary satisfaction (Study A: GFR 25–55 mL/min. 1.73m2) | Dietary satisfaction score | 220 | 221 | 3.6±1.0 | 3.8±1.0 | – | <0.05 |
| Dietary satisfaction (Study B: GFR 13–24 mL/min. 1.73m2 | Dietary satisfaction score | 65 | 59 | 3.1±0.9 | 3.6±0.9 | – | <0.01 | |
| MDRD‡ Study 2 (1996) | Decline eGFR (Study A: GFR 25–55 mL/min. 1.73m2) | Decline eGFR, baseline to 3 years | 291 | 394 | – | – | 3.8 (4.2)§ | – |
| Decline eGFR (Study B: GFR 13–24 mL/min. 1.73m2) | Decline eGFR, baseline to 3 years | 126 | 129 | – | – | 4.0 (3.1)§ | – | |
| Mekki | Total cholesterol (TC) | TC/mmol L-1 | 20 | 20 | 4.1±0.5 | 5.4±0.4 | – | <0.05 |
| Triacylglycerols (TG) | TG/mmol L-1 | 2.9±0.1 | 3.9±0.1 | – | <0.05 | |||
| Meuleman | Blood pressure | Office systolic BP, mmHg | 67 | 71 | – | – | −7.3 (−12.7 to −1.9)¶ | <0.01 |
| Office diastolic BP, mmHg | – | – | −3.8 (-6.9 to -0.6)¶ | <0.05 | ||||
| Sodium excretion | Sodium excretion rate, mmol/24 hours | – | – | 2.9 (−21.6 to 27.3)¶ | ||||
| Paes-Barreto | Change in protein intake | Change protein intake, g/day | 43 | 46 | −20.7 (−30.9%)†† | −10.5 (−15.1%)¶†† | – | 0.04 |
| Pisani | Protein intake | Change protein intake, g/kg/day | 27 | 27 | −0.1 (−0.17 to −0.03)† | −0.2 (−0.28 to −0.13)† | – | 0.04 |
| UUN excretion | Change UUN, g/day | −1.3 (−2.1 to −0.5)† | −2.8 (−3.6 to −2)† | – | 0.008 | |||
| SUN | Change SUN, mg/dL | 2.96 (−7.71 to 13.64)† | −16.63 (−27.3 to −5.96)† | – | 0.012 | |||
| Urinary phosphate excretion | Change phosphate excretion, mg/day | −27.6 (−93.7 to 38.4)† | −165.3 (−231.3 to −99.2)† | – | 0.005 | |||
| Serum phosphate concentration | Change serum phosphate, mg/dL | 0.2 (0 to 0.4)† | −0.1 (−0.3 to 0.2)† | – | 0.093 | |||
| Adherence | Met criteria, n, % | 19 (70%)‡‡ | 11 (44%)‡‡ | – | – | |||
| Rosman | Adherence (Group A1 & B: CrCl >30) | Median 24-hour urea excretion mmol/24 hours | 45 | 47 | – | – | – | <0.01 |
| Adherence (Group A2 & C: CrCl ≤30) | Median 24-hour urea excretion mmol/24 hours | 23 | 17 | – | – | – | <0.01 | |
| Saran et al | Change hydration status | Extracellular Volume, L | 29 | 29 | – | – | −1.02 (−1.48 to 0.56) | <0.001 |
| Intracellular Volume, L | – | – | −0.06 (−0.12 to 0.01) | 0.02 | ||||
|
| ||||||||
| Aoike | Cardiopulmonary | Maximal ventilation, L/min | 14 | 15 | 90.7±28.1 | 76.6±23.3 | – | 0.003 |
| parameters | Ventilatory threshold, VO2 peak, ml/kg/min | 26.1±7.0 | 24.2±7.1 | – | 0.302 | |||
| VO2 in respiratory compensation point, ml/kg/min | 21.7±5.5 | 19.0±5.6 | – | 0.073 | ||||
| Speed in respiratory compensation point, Km/h | 6.8±1.1 | 5.8±1.0 | – | <0.001 | ||||
| Functional capacity | 6MWT, minutes | 583.1±85.2 | 561.2±91.2 | – | 0.028 | |||
| Time up/go test, seconds | 5.82±1.39 | 6.42±1.11 | – | 0.001 | ||||
| Arm curl test, repetitions | 22.8±4.8 | 18.1±3.1 | – | <0.001 | ||||
| STST, repetitions | 24.0±7.1 | 18.3±4.8 | – | <0.001 | ||||
| 2-minute step test, steps | 219.3±36.7 | 179.9±36.3 | – | <0.001 | ||||
| Back scratch test, cm | 6.4±6.6 | 12.6±9.9 | – | 0.05 | ||||
| Systolic and diastolic BP | Systolic BP, mm Hg | 118.7±7.3 | 126.8±6.7 | – | 0.012 | |||
| Diastolic BP, mm HgP | 76.1±4.4 | 81.0±3.7 | – | 0.038 | ||||
| Renal function | Serum creatinine, mg/dL | 2.6±1.1 | 3.2±1.4 | – | 0.215 | |||
| eGFR, mL/min/1.73 m2 | 31.9±13.7 | 23.9±12.2 | – | 0.046 | ||||
| Barcellos | Mean change in eGFR | Change eGFR, mL/min/1.73 m2 | 76 | 74 | 61.5 (57.0 to 66.1)† | 59.0 (54.2 to 63.8)† | 0.7 (−4.0 to 5.4) | – |
| Greenwood | Mean change in eGFR | Change eGFR, mL/min/1.73 m2 | 8 | 10 | −3.8±2.8 | −8.5±6.4 | 7.8±3.0 (1.1 to 13.5) | 0.02 |
| Kao | Depression | Change depression (Beck Depression Inventory-II scale) | 45 | 49 | −3.71§§ | 1.33§§ | – | <0.01 |
| Fatigue | Change fatigue | −4.74§§ | 1.91§§ | – | <0.001 | |||
| Exercise behaviour | Change weekly exercise | 4.28§§ | −1.24§§ | – | <0.001 | |||
| Leehey et al | UPCR ratio | UPCR (mg/g) at 52 wks | 14 | 18 | 405 (225 to 1038)††† | 618 (323 to 1155)††† | – | 0.39 |
| Rossi | Physical function | 6MWT, minutes | 59 | 48 | 210.4±266 | −10±219.9 | – | <0.001 |
| STST, seconds | 26.9%±27% age prediction*** | 0.7%±12.1% age prediction*** | – | <0.001 | ||||
| Gait speed, cm | 9.5 (−36.4 to 34)††† | 0 (−9 to 13)††† | – | 0.76 | ||||
| QoL (RAND SF-36), | Role functioning/physical | 19.0±31.7 | −8.9±38.4 | – | <0.001 | |||
| mean change from | Physical functioning | 11.1±19.3 | −0.7±18.7 | – | 0.004 | |||
| baseline | Energy/fatigue | 9.8±17.6 | 0.5±18.0 | – | 0.01 | |||
| General health | 4.9±15.3 | −1.2±11.5 | – | 0.03 | ||||
| Pain | 5.7±20.0 | −3.8±24.4 | – | 0.04 | ||||
| Emotional well-being | 4.2±16.9 | −0.4±17.1 | – | 0.2 | ||||
| Social functioning | 4.2±20.8 | 1.6±22.6 | – | 0.57 | ||||
| Role functioning/emotional | 6.9±24.5 | 1.9±29.2 | – | 0.38 | ||||
| Tang | Physical function | Change 6MWT, minutes | 42 | 42 | 41.93±14.57 | −5.05±14.81 | – | <0.001 |
| Change STST, seconds | −2.68±1.95 | 0.49±2.07 | – | <0.001 | ||||
| Self-efficacy | Change self-efficacy score | 6.64±6.92 | −3.72±6.80 | – | <0.001 | |||
| Anxiety | Change HAD-A score | −1.02±1.47 | 0.21±2.17 | – | 0.003 | |||
| Depression | Change HAD-D score | −0.76±1.32 | 0.31±1.84 | – | 0.003 | |||
| QoL (KDQOL-SF), | Symptom/problem list | 2.49±4.81 | 0.38±6.97 | – | 0.007 | |||
| mean change from | Effects of kidney disease | 1.90±5.22 | −1.56±9.64 | – | 0.005 | |||
| baseline | Burden of kidney disease | −0.45±15.27 | −15.3±18.11 | – | <0.001 | |||
| SF-12 PCS | 1.08±3.60 | −0.74±4.55 | – | 0.045 | ||||
| SF-12 MCS | 1.87±5.69 | −0.73±4.53 | – | 0.002 | ||||
| Van Craenenbroeck | Peripheral endothelial function | Flow mediated dilation of brachial artery | 19 | 21 | 4.6±3.0 | 5.3±3.1 | 0.32 (−1.88 to 2.53) | 0.9 |
|
| ||||||||
| Flesher | Composite of eGFR, TC, US, UP, BP | Number of improved endpoints | 23 | 17 | 83 | 30 | 0.028 | |
| Howden | Change in CRF | VO2, ml/kg/min | 36 | 36 | 2.8±0.7 | 0.3±0.9 | – | 0.004 |
| Ishani | Composite death, hospitalisation, emergency visits, admission nursing facility | Occurrence of primary outcome/HR | 451 | 150 | 208 (46.2%) | 70 (46.7%) | – | 0.9 |
| Jiamjariyapon | Mean change in eGFR | Change eGFR, mL/min/1.73 m2 | 234 | 208 | 42.4±1.5 | 39.9±2.8 | 2.74 (0.60 to 4.50) | 0.009 |
| Joboshi and Oka | Perceived behaviour | Self-efficacy | 32 | 29 | r=0.27, U=318.5** | – | – | 0.035 |
| Self-management | r=0.29, U=310.0** | – | – | 0.026 | ||||
| Patil | 24-hour urine protein | 24-hour urine protein, g/d | 23 (B) | 22 (A),31 (C) | 1284.74±1079.94 | A: 1079.27±1269.20; C: 1187.61±756.92 | – | – |
| BMI | Change in BMI (paired t-test) | −1.95±1.10 | A: −0.15±0.38 (p=0.069); C: −2.56±0.68 (p=0.000) | – | 0.000 | |||
| Teng | Health-promotion lifestyle | Stress management | 45 | 45 | – | – | 2.76 | 0.10 |
| behaviours (HPLP-IIC) | Interpersonal relations | – | – | 3.88 | 0.05 | |||
| Health responsibility | – | – | 13.63 | 0.001 | ||||
| Physical activity | – | – | 7.50 | 0.01 | ||||
| Spiritual growth | – | – | 2.79 | 0.10 | ||||
| Nutrition | – | – | 2.62 | 0.11 | ||||
| Renal function protection knowledge | Knowledge renal function, Chinese herbs and CKD diet | – | – | No data | 0.001 | |||
| Physical function | 6MWT, minutes | 45 | 45 | 420.4±81.2 | 368.5±99.7 | – | 0.04 | |
*Unless otherwise indicated, values are shown as mean+/-SD.
†Mean change (95% CI).
‡Modification of Diet in Renal Disease (MDRD) study (Gillis et al 33, Coyne et al 48).
§Mean decline +/-SD.
¶Mean change from baseline after 6 months.
**Effect size (r) Median, Mann-Whitney's U Test.
††Mean change and % reduction from baseline values.
‡‡ Number of participants who met adherence criteria (n,%).
§§Paired T test.
¶¶ p-value calculated as p<0.05 x group interaction (Aoike 2015).
***STST results standardized as a percentage of age-predicted value using prediction formulas (Rossi 2014).
†††Median (IQR)
BMI, Body Mass Index; BP, blood pressure;CrCl, Creatinine clearance; CRF, Cardiorespiratory fitness; eGFR, estimated glomerular filtration rate; HAD-A/HAD-D, Hospital Anxiety & Depression Scale; HPLP-IIC, Health Promoting Lifestyle Profile-II Chinese version (questionnaire); KDQOL-SF, Kidney Disease & Quality of Life Short Form; 6MWT, 6 min Walk Test; SF-12 PCS/MCS, Physical and Mental Health Composite Scores; QoL, Quality of life; RAND SF-36, 36-Item Short Form Survey; STST, Sit to Stand Test; SUN, Serum urea nitrogen; UP, Urinary protein; UPCR, Urine protein to creatinine ratio; US, Urinary sodium; UUN, urinary urea nitrogen.